3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
9
Multiple Myeloma
5
Neoplasms
4
Neoplasm Metastasis
4
Kidney Neoplasms
3
Giant Cell Tumor of Bone
3
Smoldering Multiple Myeloma
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Recurrence
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Osteoblastoma
1
Neoplastic Cells, Circulating
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hypercalcemia
1
Humoral Hypercalcemia Of Malignancy
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Granuloma, Giant Cell
1
Interventions
Cyclophosphamide
22
Paclitaxel
12
Epirubicin
12
Doxorubicin
11
Trastuzumab
10
Docetaxel
10
Carboplatin
10
Taxes
7
Bevacizumab
6
pembrolizumab
5
Radiotherapy
5
Filgrastim
5
Albumin-Bound Paclitaxel
5
Neoadjuvant Therapy
4
130-nm albumin-bound paclitaxel
4
Thiotepa
3
Tamoxifen
3
Panitumumab
3
Melphalan
3
Lapatinib
3
Granulocyte Colony-Stimulating Factor
3
Fluorouracil
3
Chemotherapy, Adjuvant
3
sargramostim
2
pertuzumab
2
eribulin
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Cisplatin
2
Capecitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Inflammatory Breast Neoplasms
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled